<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01962051</url>
  </required_header>
  <id_info>
    <org_study_id>CL07123</org_study_id>
    <nct_id>NCT01962051</nct_id>
  </id_info>
  <brief_title>AMPLATZER Cardiac Plug (ACP) Latin American Post Market Observational</brief_title>
  <acronym>ACP LA</acronym>
  <official_title>AMPLATZER Cardiac Plug (ACP) Latin American Post Market Observational</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Jude Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Jude Medical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The ACP device will be clinically evaluated through a prospective, open-label, nonrandomized,
      multi-center post market clinical study.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    St. Jude Medical business decision
  </why_stopped>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the performance of the ACP device in closure of the LAA</measure>
    <time_frame>2 years post implant</time_frame>
    <description>Defined as absence of flow or flow of â‰¤3mm jet into the LAA at procedure and at 6 months, 1 year and 2 years as assessed by Transoesophageal Echocardiography (TOE).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The rate of occurrence for any reported adverse event experienced by subjects enrolled</measure>
    <time_frame>Through 2 years</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">0</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Left Atrial Appendage</condition>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>Delivery system Entry</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Amplatzer Cardiac Plug</intervention_name>
    <arm_group_label>Delivery system Entry</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects with nonvalvular atrial fibrillation (NVAF)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject must have a documented history of paroxysmal, persistent or permanent
             nonvalvular atrial fibrillation (documentation may include an electrocardiogram (ECG),
             Holter, or event recorder)

          -  Subject must have a LAA closure procedure that has already been planned or scheduled
             by his/her attending physician before entry in the study

          -  Subject must be greater than or equal to 18 years of age

        Exclusion Criteria:

          -  Subject with an implanted atrial septal defect (ASD) device or patent foramen ovale
             (PFO) device

          -  Subject underwent LAA closure procedure prior to study entry (i.e. before signing
             informed consent

          -  Subject who has a history of surgical ASD or PFO repair

          -  Subject with a history of stroke and unrepaired PFO

          -  Subject who has moderate to severe aortic or mitral valve stenosis or regurgitation
             requiring surgical or percutaneous intervention as assessed by the Investigator

          -  Subject who has a mitral or aortic prosthetic valve

          -  Subject with NYHA grade 4

          -  Subject with evidence of moderate pericardial effusion at baseline evaluation

          -  Subject who has complex atheroma with mobile plaque of the descending aorta and/or
             aortic arch

          -  Subject who has an intracardiac thrombus

          -  Subject who has carotid disease as assessed by the Investigator, requiring treatment,
             which includes revascularization and/or medical treatment

          -  Subject with active infection or active endocarditis

          -  Subject who has an acute or recent myocardial infarction (MI) or unstable angina
             (recent is defined as within 3 months of implant date)

          -  Subject who has had recent major cardiac surgical procedure (recent is defined as
             within 6 months of implant date)

          -  Subject with malignancy or other illness where life expectancy is less than one year

          -  Subject who is pregnant, breastfeeding, or desires to become pregnant during their
             first six months of follow-up

          -  Subject or legally authorized representative who is unable to provide informed consent

          -  Subject who will not be able to be followed for the duration of the clinical study

          -  Subject with any medical disorder or severe disability that would interfere with
             completion or evaluation of clinical study results (for example uncontrolled
             hypertension, uncontrolled diabetes, blood disorder, renal failure, in situ IVC
             filter)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 10, 2013</study_first_submitted>
  <study_first_submitted_qc>October 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 14, 2013</study_first_posted>
  <last_update_submitted>September 19, 2016</last_update_submitted>
  <last_update_submitted_qc>September 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No data collected as study stopped before sites activated</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

